13 March 2019 Written by CN1699 Services Article viewed 7 times (3 times in the last week)

Ovarian cancer is not the most common form of cancer, but it's among the deadliest. That's because about 70 percent of cases recur. A new study by researchers at the University of Pittsburgh, UPMC Hillman Cancer Center, Magee-Womens Research Institute (MWRI) and several other collaborating institutions targets the root of recurrence with new drugs aimed at annihilating stem-like ovarian cancer cells.

A new experimental drug, 673A, that specifically kills the stem-like cells that tend to linger after chemotherapy. In a mouse model of ovarian cancer, combined treatment with 673A and chemotherapy resulted in significantly greater survival rates.

For more information, visit: medicalxpress

The University of Pittsburgh is a state-related research university in Pittsburgh, Pennsylvania.

Read more related topics:

Ovarian Cancer | Cancer Treatment |

Source: medicalxpress

Grace T

Managing Editor - CN1699 Services